A Review of Newly Diagnosed Glioblastoma

Bryan Oronsky; Tony R Reid; Arnold Oronsky; Navjot Sandhu; Susan J Knox

doi:10.3389/fonc.2020.574012

A Review of Newly Diagnosed Glioblastoma

Front Oncol. 2021 Feb 5:10:574012. doi: 10.3389/fonc.2020.574012. eCollection 2020.

Authors

Bryan Oronsky¹, Tony R Reid², Arnold Oronsky³, Navjot Sandhu⁴, Susan J Knox⁴

Affiliations

¹ Department of Clinical Research, EpicentRx, San Diego, CA, United States.
² Department of Medical Oncology, UC San Diego School of Medicine, San Diego, CA, United States.
³ Department of Clinical Research, InterWest Partners, Menlo Park, CA, United States.
⁴ Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States.

Abstract

Glioblastoma is an aggressive and inevitably recurrent primary intra-axial brain tumor with a dismal prognosis. The current mainstay of treatment involves maximally safe surgical resection followed by radiotherapy over a 6-week period with concomitant temozolomide chemotherapy followed by temozolomide maintenance. This review provides a summary of the epidemiological, clinical, histologic and genetic characteristics of newly diagnosed disease as well as the current standard of care and potential future therapeutic prospects.

Keywords: brain tumors; cancer; glioblastoma; high-grade gliomas; radiation therapy.

Publication types

Review